reports
Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarte...
Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019 SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to facilitate the closing of the Company’s transaction with Immunic AG. As previously announced, the transaction has been approved by the stockholders of the Company and is expected to be consummated by mid-April. In connection with the closing of the transaction, Vital Therapies will change its name to Immun...
Vital Therapies, Inc. Announces Stockholder Approval of Business Combi...
Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held earlier today. Approximately 98.82% of the shares voted at the special stockholder meeting voted in favor of the Exchange Agreement proposal, with each of the other related proposals also receiving sufficient votes for approval. “We...
Vital Therapies Reminds Stockholders to Vote For the Proposed Busines...
Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG Of the Votes Received to Date, More than 98% are Voting in Favor of the Business CombinationMore Votes are Needed to Reach 50% of the Outstanding Shares Required for the Business Combination to Go ForwardEvery Vote is Important to Avoid Delay in Completion of the Business Combination SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) would like to thank its stockholders for their support of the proposed business combination with Immunic AG and remind those stockholder...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommen...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Vital Therapies Stockholders Vote “FOR” the Proposed Business Transaction With Immunic AG and All the Related Proposals SAN DIEGO, March 25, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) announced today that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both recommended that Vital Therapies stockholders vote “FOR” the proposed business combination with Immunic AG and the related proposals in the Company’s proxy statement/prospectus for the special meeting of its sto...
Vital Therapies Announces 2018 Financial Results
Vital Therapies Announces 2018 Financial Results SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the year ended December 31, 2018. Recent Developments On January 6, 2019, we entered into an exchange agreement (the “Exchange Agreement”), with Immunic AG, or Immunic, and all of the current shareholders of Immunic. Under this agreement, all Immunic shareholders will exchange all of their Immuni...
Vital Therapies and Immunic Therapeutics Announce Transaction to Creat...
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company – Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets – – Lead Program, IMU-838, an Orally Available, Small Molecule Inhibitor of DHODH, Already Advanced into Phase 2 Studies in Ulcerative Colitis – – Companies to Host Conference Call to Discuss Transaction at 8:00 a.m. ET on January 7 – SAN DIEGO and PLANEGG-MARTINSRIED, Germany, Jan. 07, 2019 (GLOB...
Vital Therapies Announces Third Quarter 2018 Financial Results
Vital Therapies Announces Third Quarter 2018 Financial Results SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the third quarter ended September 30, 2018. Recent Developments As reported in September, the Company’s VTL-308 clinical study of ELAD in the treatment of severe alcoholic hepatitis failed to meet either its primary or secondary endpoints. As a result, the Company ceased any further d...
An unfavourable environment weighs on VITAL THERAPIES INCO., which see...
The independent financial analyst theScreener just requalified the general evaluation of VITAL THERAPIES INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date October 12, 2018, the closing price ...
Vital Therapies Provides Strategic Update
Vital Therapies Provides Strategic Update SAN DIEGO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced updates on the Company’s ongoing strategy to preserve its cash and maximize shareholder value. To further that objective, the Company has retained Ladenburg Thalmann & Co. Inc. as its strategic financial advisor to assist in the review of the Company's business and assets and exploration of strategic opportunities for enhancing stoc...
Vital Therapies to Present at the 19th International Liver Support Mee...
Vital Therapies to Present at the 19th International Liver Support Meeting SAN DIEGO, Sept. 29, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced that additional data from its VTL-308 clinical trial will be presented today at the 19th International Liver Support Meeting in Rostock-Warnemunde, Germany. The presentation, titled "Update on ELAD Study VTL-308", will be made by Nikolaos T. Pyrsopoulos, M.D., Ph.D., Professor and Chief, Division of...
- Jonathan Moreland
REFR RESEARCH FRONTIERS INC.
PFS PROVIDENT FINANCIAL SERVICES INC.
NGL NGL ENERGY PARTNERS LP
MIC MACQUARIE INFRASTRUCTURE CORPORATION
MCRB SERES THERAPEUTICS
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
ICON ICONIX BRAND GROUP
HWCC HOUSTON WIRE & CABLE
FOLD AMICUS THERAPEUTICS INC.
FMNB FARMERS NATIONAL BANC CORP.
FIT FITBIT INC. CLASS A
FB FACEBOOK INC. CLASS A
EBSB MERIDIAN BANCORP INC
CTLT CATALENT INC
BLPH BELLEROPHON THERAPEUTICS
AGFS AGROFRESH SOLUTIONS
IRIX IRIDEX CORP.
VTL VITAL THERAPIES INC
KFS KINGSWAY FINANCIAL SERVICES
KNDI KANDI TECHNOLGIES GROUP (N SHARES)
NSA NATIONAL STORAGE AFFILIATES TRUST
A2PR0Y SCULPTOR CAPITAL MANAGEMENT INC (A)
SGMS SCIENTIFIC GAMES CORPORATION
CNBKA CENTURY BANCORP INC. CL A
CWH CAMPING WORLD HOLDINGS INC. CLASS A
NNBR NN
GWRS INC.
PFE GLOBAL WATER RESOURCES
SNAP PFIZER INC.
EDGW SNAP INC. CLASS A
VERI EDGEWATER TECHNOLOGY INC.
VREX VERITONE INC.
ETP VAREX IMAGING CORPORATION
ODT ENERGY TRANSFER PARTNERS
ITUS L.P.
APLS ODONATE THERAPEUTICS INC
SSP ITUS CORP
EOLS APELLIS PHARMACEUTICALS
LIFE THE E.W. SCRIPPS COMPANY
KDP EVOLUS INC
BHC LIFE TECHNOLOGIES CORPORATION
MGY KEURIG DR PEPPER INC.
OGEN BAUSCH HEALTH COMPANIES INC.
LGCYQ MAGNOLIA OIL & GAS CORP. CLASS A
ORAGENICS INC.
LEGACY RESERVES
- Jonathan Moreland
PFS PROVIDENT FINANCIAL SERVICES INC.
HWCC HOUSTON WIRE & CABLE
FOLD AMICUS THERAPEUTICS INC.
CTLT CATALENT INC
CLMT CALUMET SPECIALTY PRODUCTS PARTNERS L.P.
BLPH BELLEROPHON THERAPEUTICS
VTL VITAL THERAPIES INC
KFS KINGSWAY FINANCIAL SERVICES
A2PR0Y SCULPTOR CAPITAL MANAGEMENT INC (A)
CNBKA CENTURY BANCORP INC. CL A
CWH CAMPING WORLD HOLDINGS INC. CLASS A
NNBR NN
PFE INC.
LLEXQ PFIZER INC.
VERI LILIS ENERGY
ETP VERITONE INC.
BHC ENERGY TRANSFER PARTNERS
MGY L.P.
BAUSCH HEALTH COMPANIES INC.
MAGNOLIA OIL & GAS CORP. CLASS A
Vital Therapies Announces That Topline Results of VTL-308 Fail to Achi...
Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival SAN DIEGO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that, while there was a numerical improvement in survival in the ELAD-treated group between three months and one year following randomization, the VTL-308 study failed to meet the primary endpoint of a significant improvement in overall survi...
Vital Therapies Announces Second Quarter 2018 Financial Results
Vital Therapies Announces Second Quarter 2018 Financial Results - On Track for Release of VTL-308 Topline Results in Second Half of September 2018 SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the second quarter ended June 30, 2018. “This is an exciting time for the Company. We are diligently working toward database lock for VTL-308 and expect to report topline results in the second half of September,” s...
Vital Therapies Announces Upcoming Second Quarter Financial Results Co...
Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its second quarter 2018 financial results after the market closes on Tuesday, August 7, 2018 followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss...
Vital Therapies Joins the Russell 3000 Index®
Vital Therapies Joins the Russell 3000 Index® SAN DIEGO, June 25, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, announced it has been added as a member of the broad-market Russell 3000® Index, effective after the U.S. market opens today, as part of the 2018 Russell indexes reconstitution. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of May 11, ranking them by total market capitalization. Membership in the Russe...
Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 563...
Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) SAN DIEGO, June 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today reported a grant under its Amended and Restated 2017 Inducement Equity Incentive Plan to a new employee who joined Vital Therapies on June 11, 2018. The grant made June 11, 2018 is an award of a nonstatutory stock option to purchase up to a total of 60,000 shares of Vital Therapies’ common stock. The option...
Vital Therapies to Present at the Jefferies 2018 Global Healthcare Con...
Vital Therapies to Present at the Jefferies 2018 Global Healthcare Conference SAN DIEGO, June 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that Russell J. Cox, Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference in New York City at 8:30 a.m. ET on Friday, June 8. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: . An archive of the pre...
Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial ...
Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial Results - VTL-308 Enrollment Nears Completion with 147 Subjects Enrolled as of March 12- On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and fiscal year ended December 31, 2017. “As VTL-308 nears completion, I am proud of the job our team has done in de...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.